At present, the molecular classification of gliomas is mandatory to predict outcome and in therapeutic decision-making, as patients with isocitrate dehydrogenase (IDH)-mutant gliomas have a significantly better prognosis as compared to IDH-wild-type tumors, with a differentiated mutational profile between the two groups. Here, IDH1 is linked to central nervous system cancer.